What is Cogent Biosciences, Inc.'s revenue?

Cogent Biosciences, Inc. (COGT) generated $7.9M in revenue over the trailing twelve months, down 65.0% year over year.

Is Cogent Biosciences, Inc. profitable?

Cogent Biosciences, Inc. is not currently profitable: it reported a net loss of $354.3M over the trailing twelve months, a -950.4% net margin.

What is Cogent Biosciences, Inc.'s earnings per share?

Cogent Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-2.17.

Where does Cogent Biosciences, Inc.'s income statement data come from?

Every line is extracted from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Cogent Biosciences, Inc. COGT Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Research and development	$269.78M+16.0%	$232.66M+33.9%	$173.76M+42.9%	$121.63M+118%
General and administrative	$63.58M+46.9%	$43.28M+25.9%	$34.38M+31.1%	$26.21M+33.5%
Total costs & expenses	$333.36M+20.8%	$275.94M+32.6%	$208.13M+40.8%	$147.84M+95.7%
Operating income	-$333.36M-20.8%	-$275.94M-32.6%	-$208.13M-40.8%	-$147.84M-95.7%
Interest expense	$3.06M—	——	——	——
Interest income	$14.69M-18.8%	$18.09M+38.3%	$13.08M+228%	$3.99M+754%
Other income (expense), net	——	$20.08M+27.7%	$15.72M+107%	$7.6M+132%
Gain (loss) on extinguishment of debt	-$7.18M—	$0—	$0—	——
Net income	-$328.94M-28.6%	-$255.86M-33.0%	-$192.41M-37.2%	-$140.24M-94.0%
Diluted earnings per share	-$2.16-11.3%	-$1.94-0.5%	-$1.93-2.1%	-$1.89-1.1%
Basic earnings per share	-$2.16-11.3%	-$1.94-0.5%	-$1.93-2.1%	-$1.89-1.1%
Weighted-average shares, diluted	494.2M+21.1%	408.1M+31.1%	311.3M+39.7%	222.8M+46.7%
Weighted-average shares, basic	494.2M+21.1%	408.1M+31.1%	311.3M+39.7%	222.8M—
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$329.03M-28.7%	-$255.66M-33.1%	-$192.06M-36.8%	-$140.35M-94.3%
Gain Loss On Sale Of Property Plant Equipment	——	$0+100%	-$8K—	$0—
Other comprehensive income (loss)	——	——	$350K—	——
Net unrealized gains (losses) on securities still held	——	——	$350K—	——
Other income, net (Note 6)	-$20K-101%	$1.99M+110%	$950K—	——
EBIT	-$333.36M-20.8%	-$275.94M-32.6%	-$208.13M-40.8%	-$147.84M-95.7%
EBITDA	-$330.79M-20.9%	-$273.5M-32.9%	-$205.86M-40.0%	-$147M-94.9%
EBITDA	-$330.79M-20.9%	-$273.5M-32.9%	-$205.86M-40.0%	-$147M-94.9%
EBIT	-$333.36M-20.8%	-$275.94M-32.6%	-$208.13M-40.8%	-$147.84M-95.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Cogent Biosciences, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cogent Biosciences, Inc.'s revenue?: Cogent Biosciences, Inc. (COGT) generated $7.9M in revenue over the trailing twelve months, down 65.0% year over year.
Is Cogent Biosciences, Inc. profitable?: Cogent Biosciences, Inc. is not currently profitable: it reported a net loss of $354.3M over the trailing twelve months, a -950.4% net margin.
What is Cogent Biosciences, Inc.'s earnings per share?: Cogent Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-2.17.
Where does Cogent Biosciences, Inc.'s income statement data come from?: Every line is extracted from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.